Appili Therapeutics mails circular in connection with special meeting

Appili Therapeutics (APLIF) announces its special meeting of shareholder date. The notice of the special meeting of shareholders and management information circular will be available on the Company’s website. Appili’s board of directors recommend that shareholders vote in favour of the resolution pursuant to which Aditxt Inc. (ADTX), through its wholly-owned subsidiary, Adivir, Inc., agreed to acquire all of the issued and outstanding Class A common shares of the Company by way of a court-approved plan of arrangement. Under the terms of the Arrangement, for each Appili Share, shareholders will receive (i) US$ 0.467 in cash and 0000686251 of a share of Adixt common stock. This Amalgamation represents a significant premium to Appili’s recent trading price, and assuming the completion of the transaction, provides shareholders with immediate value. In addition to the diversifying Appili’s shareholders’ investments, the combined enterprise should enhance access to capital and accelerate the development of Appili’s programs.